We have assembled a preeminent team of vaccinologists and vaccine developers to harness the Xpress CF technology to create best-in-class vaccines to prevent deadly infectious diseases. Collectively they have invented and/or developed most of the blockbuster vaccines available today, including vaccines to prevent pneumococcus (Prevnar® & Prevnar 13®), human papilloma virus (Gardasil®), rotavirus (Rotashield® & Rotateq®), herpes zoster (Zostavax®), measles, mumps, rubella and varicella virus (Proquad®), meningococcus (Menjugate®), influenza (FluMist®), dengue virus (Dengvaxia®), Japanese encephalitis (ChimeriVax-JE®), West Nile virus (Prevenile®), yellow fever (Arilvax®), and smallpox, among others.

Trevor Hallam, PhD

Dr. Hallam has more than 25 years of experience in pharmaceutical discovery and development.  He joined Sutro Biopharma as CSO in late 2010.  Since then Dr. Hallam has shaped Sutro’s biochemical synthesis technology to generate a disruptive discovery and manufacturing platform for novel best-in-class bispecific and antibody-drug conjugate protein therapeutics.  Prior to Sutro, Dr. Hallam has held several senior R&D positions in the US and Europe, most recently Vice President Biologics, Vice President U.S. Medical Affairs, and Vice President, Research and Pre-clinical Development at AstraZeneca.  He began his pharmaceutical career in the UK working for Smith Kline & French followed by senior management positions at Glaxo and Roche.  Dr. Hallam conducted his post-doctoral training in the laboratory of Timothy Rink MD DSc at the Physiological Laboratory, University of Cambridge after receiving his Ph.D. in Biochemistry from King’s College, University of London.

Tony Ford-Hutchinson, PhD

Dr. Ford-Hutchinson was either head of Vaccine R&D at Merck or responsible for Vaccine Research during which time four important vaccines were discovered and developed: Gardasil®, Zostavax®, Proquad® and Rotateq®. His career at Merck started at Merck Frosst Canada where he spent 17 years moving from Director of Pharmacology to SVP and Site Head. During his time in Canada, the laboratories there developed multiple approved products, including Singulair®, for the treatment of adult and pediatric asthma and allergic rhinitis, and selective COX-2 inhibitors for the treatment of osteoarthritis and pain, becoming the most productive discovery unit within Merck. In 1998, Dr. Hutchinson moved to Pennsylvania to head the basic research efforts worldwide. As an EVP, he became responsible for franchise strategies in multiple disease areas, including Vaccines and Infectious Diseases. He also served as the Chairman of the Board, Hilleman Laboratories, a JV between Merck and the Wellcome Trust with vaccine development laboratories in New Delhi, India.  After 32 years at Merck, he retired in 2012 and has subsequently served on several biotech boards and SABs, including Okairos AG, a vaccine platform company based around viral vectors (acquired by GlaxoSmithKline), Ligocyte Pharmaceuticals, a company developing a vaccine against norovirus infection (acquired by Takeda Pharmaceuticals), Novira Pharmaceuticals, a small molecule start-up developing anti-viral capsid inhibitors (acquired by Johnson & Johnson) and is currently an SAB member of Inovio Pharmaceuticals, a vaccine platform company based around in vivo DNA electroporation and Hookipa AG, a vaccine company based around a novel viral expression system. He is also a member of the Translational Fund Committee at the Wellcome Trust, and a Board Member of SAGE Bionetworks, a not for profit organization aiming to improve the understanding and treatment of human disease through data-driven predictive modeling. Dr. Hutchinson obtained his BSc, MSc and PhD from the Universities of Birmingham, Warwick and London.

Thomas P. Monath, MD

Tom is currently CSO and COO of BioProtection Systems, the infectious disease subsidiary of NewLink Genetics, where he is leading the development of the most advanced Ebola virus vaccine in partnership with Merck. The vaccine was recently shown to provide 100% efficacy after a single dose in Phase 3. He has over 25 years operating experience in the healthcare biotechnology industry, and is a former partner in the Pandemic and Biodefense Fund at Kleiner Perkins Caufield & Byers. Before joining NewLink Genetics, Tom was CMO for Hookipa Biotech, Juvaris and Xcellerex. Between 1992 & 2006, he was CSO and Executive Director of Acambis prior to its acquisition by Sanofi Pasteur, where he directed R & D on vaccines against dengue, Japanese encephalitis, West Nile, yellow fever, Clostridium difficile, and smallpox. The dengue vaccine that he invented, Dengvaxia®, was recently approved for human use and is one of four vaccines he developed that are now licensed. He currently serves on the boards of Vaxxinnate, Juvaris, Sentinext, RapidMicro Biosystems, and US Biologic. Before joining industry, Tom served in the uniformed services of the US Army and US Public Health Service for 24 years prior to retiring as a Colonel. He was Director, Division of Vector-Borne Viral Diseases at the CDC and Prevention and Chief of the Virology Division at USAMRIID. Dr. Monath received his undergraduate degree and MD from Harvard. Tom has received many prestigious awards, including the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), the Walter Reed Medal (2002) and the James H. Steele Gold-Headed Cane Award (2015). He has served on numerous government and international committees on infectious diseases, biosecurity, WHO expert committees and the National Vaccines.

Jeffrey Almond, PhD

Dr. Almond is Visiting Professor of Microbiology at the William Dunn School of Pathology, University of Oxford and is an Oxford Martin Fellow with the Oxford Martin Programme on Vaccines.  Before that he  was Vice President and Head of Discovery Research and External R&D at Sanofi Pasteur. His scientific contributions include the first demonstration that a single gene can determine the host range of influenza virus – a finding highly relevant to understanding evolution of new pandemic strains; completion of the genetic map of an avian influenza virus, and the first detailed description of the proteins of Influenza B virus. He has also made major contributions to our understanding of poliovirus and its vaccines. In 1985 as a young academic Dr. Almond won the Fleming Award for outstanding contribution to microbiological research by a young microbiologist in the UK, and the pace and extent of his contributions have not diminished. In his previous role at Sanofi Pasteur, he was responsible for the scientific rationale underpinning approximately 30 vaccine projects covering viruses, bacteria and eukaryotic parasites. He is an elected Fellow of the American Academy of Microbiology and in 1999 was awarded the Ivanovsky Medal for “Contributions to the Development of Virology” by The Scientific Council of Virology of Russian Academy of Medical Sciences. He is a Fellow of the UK Academy of Medical Sciences and has served on numerous scientific committees in the UK and beyond, including the governing body of the Medical Research Council.